BioPharmX has conducted research that suggests potent antiproliferative and apoptotic effects of molecular iodine, the active ingredient in Violet iodine, on two types of breast cancer cell lines.
BioPharmX researchers analyzed the impact of molecular iodine on gene expression and antiproliferative changes in the luminal A breast cancer-derived cell line (MCF-7), the triple negative breast cancer cell line (MDA-MB231) and primary human mammary epithelial cells from a healthy donor. They found expressions of nuclear hormone receptors PPARs and RR were up-regulated and BCL-2 and Caspase 3, both regulators of cell death, were increased. This suggests that molecular iodine can specifically inhibit cellular proliferation and drive cell death in certain breast cancer cell lines without apparent toxicity to normal breast cells.
The researchers’ gene expression analysis using qRT-PCR also confirmed that key cell cycle genes responsible for controlling G1-S phase transition were significantly up-regulated.
The findings of the company’s in vitro research studies demonstrate that molecular iodine exhibits antiproliferative and apoptotic effects in mammary cancer cell lines and further elucidates molecular iodine’s cellular mechanism of action in these breast cancer cells.